| Not Yet Recruiting | Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metast NCT06093425 | Suzhou Transcenta Therapeutics Co., Ltd. | Phase 3 |
| Recruiting | A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophag NCT07392892 | Pfizer | Phase 2 / Phase 3 |
| Recruiting | Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer NCT07482566 | Nurettin Şahin | N/A |
| Not Yet Recruiting | The Efficacy and Safety of Laparoscopic Proximal Gastrectomy With LPG-tbROSF Versus LTG for Localized Proximal NCT07260461 | First Affiliated Hospital of Wenzhou Medical University | N/A |
| Recruiting | Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastat NCT07315854 | Beijing Friendship Hospital | Phase 2 |
| Active Not Recruiting | A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastati NCT07143604 | AstraZeneca | Phase 2 |
| Recruiting | A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ C NCT07110571 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 2 |
| Recruiting | A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas NCT06999187 | Dren Bio | Phase 1 |
| Recruiting | Study for AZD4360 in Participants With Advanced Solid Tumours NCT06921928 | AstraZeneca | Phase 1 / Phase 2 |
| Active Not Recruiting | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors NCT06714617 | SystImmune Inc. | Phase 1 |
| Recruiting | Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or NCT06731478 | Daiichi Sankyo | Phase 3 |
| Completed | Retrospective Evaluation of Nivolumab in Adjuvant Esophageal Cancer/Gastroesophageal Junction Cancer NCT06499298 | Bristol-Myers Squibb | — |
| Recruiting | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastro NCT06532006 | Shanghai Henlius Biotech | Phase 3 |
| Completed | A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Ca NCT06585501 | Daiichi Sankyo | — |
| Recruiting | Registry for Esophageal and Gastroesophageal Junction Cancer NCT06558786 | Memorial Sloan Kettering Cancer Center | — |
| Not Yet Recruiting | Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer: NCT06411171 | xiaohua li | Phase 3 |
| Recruiting | AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or NCT06346392 | AstraZeneca | Phase 3 |
| Completed | A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesoph NCT06452329 | Bristol-Myers Squibb | — |
| Recruiting | Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors NCT06293898 | SystImmune Inc. | Phase 1 |
| Recruiting | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 NCT06219941 | AstraZeneca | Phase 2 |
| Recruiting | Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG) NCT06101277 | University of California, Davis | N/A |
| Recruiting | IKS014 in Advanced Solid Tumors That Express HER2 NCT05872295 | Iksuda Therapeutics Ltd. | Phase 1 |
| Active Not Recruiting | Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Tr NCT05480384 | Brown University | Phase 2 |
| Active Not Recruiting | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors NCT05858736 | OncoC4, Inc. | Phase 1 |
| Recruiting | CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esoph NCT05187182 | Washington University School of Medicine | Phase 1 |
| Active Not Recruiting | Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Me NCT05539430 | Legend Biotech USA Inc | Phase 1 |
| Recruiting | Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma NCT05687357 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 2 |
| Not Yet Recruiting | TCRx_T Cells for Advanced or Recurrent Gastric/Gastroesophageal Junction Cancer After Failure of First Chemoth NCT05447234 | Second Affiliated Hospital, School of Medicine, Zhejiang University | EARLY_Phase 1 |
| Unknown | Single-center, Multi-cohort Exploratory Phase Ib/II Clinical Study of First-line Treatment of Unresectable Loc NCT05608785 | Henan Cancer Hospital | Phase 1 / Phase 2 |
| Unknown | A Clinical Study of Laparoscopic Proximal Gastrectomy Based on PTST(Parachute-tunnel- Style Technique) Esophag NCT06217991 | Tang-Du Hospital | N/A |
| Recruiting | Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cance NCT06121700 | Fudan University | Phase 2 |
| Unknown | A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer o NCT05395780 | Maxinovel Pty., Ltd. | Phase 2 |
| Active Not Recruiting | A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously U NCT05322577 | Amgen | Phase 1 / Phase 2 |
| Recruiting | XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esopha NCT05494060 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Recruiting | Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma NCT05439993 | Hallym University Medical Center | Phase 1 / Phase 2 |
| Terminated | PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors NCT05233436 | Pfizer | Phase 1 |
| Active Not Recruiting | A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer NCT04931654 | AstraZeneca | Phase 1 / Phase 2 |
| Unknown | Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction NCT06250894 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Terminated | A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persi NCT04510285 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Withdrawn | STRENGTH Expansion NCT04520867 | University of Colorado, Denver | — |
| Completed | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastr NCT04882241 | Merck Sharp & Dohme LLC | Phase 3 |
| Active Not Recruiting | A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors NCT04396821 | Suzhou Transcenta Therapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislel NCT04276493 | BeiGene | Phase 1 / Phase 2 |
| Completed | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Can NCT04082364 | MacroGenics | Phase 2 / Phase 3 |
| Unknown | Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ NCT04061928 | Peking University | Phase 1 / Phase 2 |
| Completed | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies NCT03652077 | Incyte Corporation | Phase 1 |
| Completed | Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage for Esophageal or Junctional Carcin NCT03529266 | Sun Yat-sen University | Phase 2 |
| Recruiting | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors NCT03526835 | Merus B.V. | Phase 1 / Phase 2 |
| Completed | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastr NCT03221426 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Can NCT02872116 | Bristol-Myers Squibb | Phase 3 |
| Completed | Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer NCT02501603 | Yonsei University | Phase 2 |
| Completed | FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES) NCT02661971 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 / Phase 3 |
| Completed | FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer NCT02581462 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 / Phase 3 |
| Terminated | Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gast NCT02726399 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | PET/MR-imaging to Differentiate Between Responders and Non-responders Receiving Preoperative Chemotherapy NCT02433301 | Rikshospitalet University Hospital | — |
| Completed | A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer NCT02178956 | Sumitomo Pharma America, Inc. | Phase 3 |
| Completed | Significance of Peritoneal Washing Cytology Before and After Neoadjuvant Chemotherapy in Patients With Esophag NCT02085564 | Rigshospitalet, Denmark | — |
| Completed | A Nutritional Management Algorithm in Older Patients With Locally Advanced Esophageal Cancer NCT02027948 | Memorial Sloan Kettering Cancer Center | N/A |
| Terminated | Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesopha NCT01813253 | Kuhnil Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric NCT01743365 | Hellenic Cooperative Oncology Group | Phase 2 |
| Completed | A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvan NCT01748773 | Hoffmann-La Roche | Phase 2 |
| Terminated | A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus NCT01774851 | Merrimack Pharmaceuticals | Phase 2 |
| Unknown | Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer NCT01747707 | Chinese Academy of Medical Sciences | Phase 2 |
| Completed | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumo NCT01576666 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Gastric Epidemiology Study in Korea NCT02538562 | Hoffmann-La Roche | — |
| Completed | Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer NCT00917462 | Memorial Sloan Kettering Cancer Center | Phase 2 |